GSK plc (GSK)
NYSE: GSK · IEX Real-Time Price · USD
39.35
-0.01 (-0.03%)
Jul 19, 2024, 4:00 PM EDT - Market closed
GSK Employees
GSK plc had 70,212 employees as of December 31, 2023. The number of employees increased by 812 or 1.17% compared to the previous year.
Employees
70,212
Change (1Y)
812
Growth (1Y)
1.17%
Revenue / Employee
$561,304
Profits / Employee
$81,877
Market Cap
80.24B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 70,212 | 812 | 1.17% |
Dec 31, 2022 | 69,400 | -20,696 | -22.97% |
Dec 31, 2021 | 90,096 | -3,970 | -4.22% |
Dec 31, 2020 | 94,066 | -5,371 | -5.40% |
Dec 31, 2019 | 99,437 | 3,947 | 4.13% |
Dec 31, 2018 | 95,490 | -2,972 | -3.02% |
Dec 31, 2017 | 98,462 | -838 | -0.84% |
Dec 31, 2016 | 99,300 | -1,955 | -1.93% |
Dec 31, 2015 | 101,255 | 3,334 | 3.40% |
Dec 31, 2014 | 97,921 | -1,530 | -1.54% |
Dec 31, 2013 | 99,451 | -37 | -0.04% |
Dec 31, 2012 | 99,488 | 2,099 | 2.16% |
Dec 31, 2011 | 97,389 | 928 | 0.96% |
Dec 31, 2010 | 96,461 | -3,452 | -3.46% |
Dec 31, 2009 | 99,913 | 910 | 0.92% |
Dec 31, 2008 | 99,003 | -4,480 | -4.33% |
Dec 31, 2007 | 103,483 | 788 | 0.77% |
Dec 31, 2006 | 102,695 | 1,967 | 1.95% |
Dec 31, 2005 | 100,728 | 709 | 0.71% |
Dec 31, 2004 | 100,019 | -900 | -0.89% |
Dec 31, 2003 | 100,919 | -3,580 | -3.43% |
Dec 31, 2002 | 104,499 | -2,971 | -2.76% |
Dec 31, 2001 | 107,470 | -47 | -0.04% |
Dec 31, 2000 | 107,517 | -1,524 | -1.40% |
Dec 31, 1999 | 109,041 | -7,780 | -6.66% |
Dec 31, 1998 | 116,821 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
HCA Healthcare | 310,000 |
CVS Health | 300,000 |
Becton, Dickinson and Company | 73,000 |
Cigna | 72,500 |
Humana | 67,600 |
McKesson | 51,000 |
Bristol-Myers Squibb Company | 34,100 |
Edwards Lifesciences | 19,800 |
GSK News
- 10 days ago - GSK Begins Shipping Influenza Vaccine Doses for 2024-25 Season - Business Wire
- 16 days ago - Will GSK Stock Rebound To Its 2022 Highs Of $47? - Forbes
- 18 days ago - GSK To Spend Up to $1.56B for Rights to Potential COVID-19, Flu Vaccines - Investopedia
- 18 days ago - GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines - Barrons
- 18 days ago - GSK Secures mRNA Vaccines For Bird Flu, COVID And Seasonal Flu From Struggling Biotech CureVac - Forbes
- 19 days ago - CureVac's stock soars on GSK's $1.56 billion deal for its COVID-19 and flu vaccines - Market Watch
- 19 days ago - GSK and CureVac to Restructure Collaboration into New Licensing Agreement - Accesswire
- 19 days ago - GSK buys full rights to make COVID, influenza vaccines from CureVac - Reuters